Lexeo Therapeutics
The Manager/Senior Manager, CMC Quality Control (QC) provides strategic and operational oversight of quality control activities for Lexeo's gene therapy programs. This role serves as the QC lead for external contract testing laboratories, analytical lifecycle management, stability programs, and release testing support. The position requires technical expertise in analytical testing and experience overseeing external laboratories to drive cross-functional CMC initiatives.
Headquarters
New York, New York, United States
Company Size
11-50 employees
Founded
2018
Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company advances high-impact genetic medicine candidates targeting genetically mediated cardiovascular diseases—including Friedreich ataxia, arrhythmogenic cardiomyopathy, desmoplakin cardiomyopathy, and hypertrophic cardiomyopathy—as well as APOE4-associated Alzheimer's disease. Building on research from Weill Cornell Medicine and UC San Diego, Lexeo prioritizes efficient development, advanced manufacturing, and strategic partnerships to deliver curative genetic therapies.
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
2 weeks ago
Lexeo Therapeutics Announces Closing of Public Offering and
Oct 20, 2025
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Lexeo Therapeutics.
18% above the average for this role
Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO)
Nov 6, 2025